# Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

> **NCT00102752** · PHASE1,PHASE2 · COMPLETED · sponsor: **Threshold Pharmaceuticals** · enrollment: 47 (—)

## Conditions studied

- Neoplasms
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Glufosfamide
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00102752
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 47 (—)
- **Last updated:** 2009-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102752, "Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00102752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*